Agilent Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma
Agilent Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify Urothelial Carcinoma Patients for Treatment With KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., August 8, 2018 Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labeled for an... Read more